Contingency Fees

Investors File Suit After Immutep’s Phase III Lung Cancer Trial Is Stopped and ADRs Collapse

Multiple law firms are recruiting Immutep ADR holders to seek lead‑plaintiff status by July 6 because plaintiffs say company statements misled the market about the trial’s progress.